Objective: To describe the successful use of high-dose enoxaparin therapy (1.5 mg/kg subcutaneously twice daily) to attain a therapeutic anti-factor Xa (anti-Xa) level in a cancer patient with heparin resistance.
Case Summary: A proven heparin-resistant patient with venous thromboembolism (VTE) and lung cancer who required approximately 66 000 units of unfractionated heparin daily was successfully transitioned to an off-label high-dose enoxaparin (OLHDE) 1.5 mg/kg subcutaneously twice daily. The patient was maintained on this same dose, and therapeutic levels were confirmed via use of the anti-Xa monitoring test. The patient was able to be discharged from the medical floor on this same dose with no further complications of VTE noted. No adverse events from this dosing were observed during the duration of therapy.
Discussion: Options for overcoming heparin resistance are limited to case reports and small studies. The best course of treatment in the cancer patient is unclear. OLHDE allowed for the transition from intravenous to subcutaneous medication and transition off the medical floor. This case supports the use of OLHDE as a therapeutic option in heparin-resistant patients with cancer. Further study is needed to confirm the efficacy of OLHDE in this patient population.
Conclusion: High-dose enoxaparin may be an option to treat cancer patients with confirmed heparin resistance and venous thromboembolism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1060028014554649 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case Report: Smoking as the risk factor of persistent STEMI after primary percutaneous coronary intervention: how it could be happen?
F1000Res
November 2024
Cardiovascular, Mataram University, Mataram, West Nusa Tenggara, 83126, Indonesia.
Background: Acute coronary syndrome (ACS) remains one of the leading causes of death worldwide. Smoking may also increase the risk of developing ACS. The most advantageous therapy is percutaneous coronary intervention.
View Article and Find Full Text PDFEvaluation of the Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Moderate-to-Severe Hospitalized COVID-19 Patients: A Randomized, Open-Label Parallel-Group Study.
Can J Infect Dis Med Microbiol
May 2024
Centre for Occupational and Environmental Health (COEH), Maulana Azad Medical College, New Delhi, India.
Purpose: Since February 2020, the world has been overwhelmed by the SARS-CoV-2 outbreak, and several patients suffered interstitial pneumonia and respiratory failure requiring mechanical ventilation, threatening the capability of healthcare systems to handle this amount of critical cases. Intravenous immunoglobulins (IVIG) possess potential immunomodulatory properties beneficial for COVID-19 patients, yet evidence supporting IVIG as adjunctive therapy remains sparse. This study evaluated the outcomes of adjunctive IVIG with the standard of care (SoC) in moderate-to-severe COVID-19 patients.
View Article and Find Full Text PDFHistidine-Rich Glycoprotein Modulates the Toxic Effects of High-Dose Polyphosphate in Mice.
Arterioscler Thromb Vasc Biol
July 2024
Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada (R.A.M., J.Z., J.C.F., J.I.W.).
Background: Polyphosphate (polyP), a procoagulant released from platelets, activates coagulation via the contact system and modulates cardiomyocyte viability. High-dose intravenous polyP is lethal in mice, presumably because of thrombosis. Previously, we showed that HRG (histidine-rich glycoprotein) binds polyP and attenuates its procoagulant effects.
View Article and Find Full Text PDFInvestigation of the effects of different drugs on the prevention of intrapleural adhesion in a rat model.
Turk Gogus Kalp Damar Cerrahisi Derg
January 2024
Department of Chest Surgery, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye.
Background: The aim of this study was to investigate the antifibrinolytic and anti-inflammatory effects of hesperidin, tenoxicam and enoxaparin on intrapleural adhesions in an experimental rat model.
Methods: A total of 52 healthy adult male Wistar Albino rats from the same colony were randomly divided into six groups as sham (Group 1), surgical control (Group 2), low-dose hesperidin (Group 3), high-dose hesperidin (Group 4), tenoxicam (Group 5), and enoxaparin (Group 6). All subjects underwent left thoracotomy and except for the sham group, an adhesion model was applied and, postoperatively, the drugs were administered intraperitoneally.
Comparison of the safety and efficacy for different regimens of pharmaco-prophylaxis among severely burned patients: a randomized controlled trial.
Eur J Trauma Emerg Surg
April 2024
Intensive Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Article Synopsis
- The study investigates the safety and feasibility of different VTE prophylactic treatments in critically ill burn patients admitted to the ICU.
- Conducted as a pilot randomized controlled trial, patients received either high-dose or standard-dose enoxaparin or unfractionated heparin, with various outcomes related to bleeding assessed.
- Results showed a low recruitment rate but high consent rate, with some instances of bleeding, indicating no major safety issues with the prophylaxis options tested.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!